Igor P Dmitriev
Overview
Explore the profile of Igor P Dmitriev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rice-Boucher P, Kashentseva E, Dmitriev I, Guo H, Tremblay J, Shoemaker C, et al.
bioRxiv
. 2025 Feb;
PMID: 39974927
Safe and efficient nucleic acid delivery to targeted cell populations remains a significant unmet need in the fields of cell and gene therapy. Towards this end, we pursued Adenoviral vectors...
2.
Gagne M, Flynn B, Andrew S, Marquez J, Flebbe D, Mychalowych A, et al.
Nat Immunol
. 2024 Sep;
25(10):1913-1927.
PMID: 39227514
A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge...
3.
Hamed H, Yacoub A, Park M, Eulitt P, Dash R, Sarkar D, et al.
Mol Ther
. 2024 Aug;
32(12):4524.
PMID: 39214081
No abstract available.
4.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):578.
PMID: 38360936
No abstract available.
5.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):537-551.
PMID: 38337035
A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC). Here, we update this vaccine by creating ChAd-SARS-CoV-2-BA.5-S, which encodes...
6.
Geng K, Rice-Boucher P, Kashentseva E, Dmitriev I, Lu Z, Goedegebuure S, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005953
mRNA vaccines have attracted widespread research attention with clear advantages in terms of molecular flexibility, rapid development, and potential for personalization. However, current mRNA vaccine platforms have not been optimized...
7.
Gagne M, Flynn B, Andrew S, Flebbe D, Mychalowych A, Lamb E, et al.
bioRxiv
. 2023 Nov;
PMID: 37986823
Graphical Abstract:
8.
Rice-Boucher P, Mendonca S, Alvarez A, Sturtz A, Lorincz R, Dmitriev I, et al.
Mol Ther
. 2023 Jul;
31(9):2600-2611.
PMID: 37452494
B cells are the antibody-producing arm of the adaptive immune system and play a critical role in controlling pathogens. Several groups have now demonstrated the feasibility of using engineered B...
9.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
bioRxiv
. 2023 May;
PMID: 37205450
We previously described a nasally delivered monovalent adenoviral-vectored SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC) that is currently used in India as a primary or booster immunization. Here, we...
10.
Lu Z, Li J, Dmitriev I, Kashentseva E, Curiel D
ACS Nano
. 2022 Jun;
16(7):10443-10455.
PMID: 35749339
The capacity to efficiently deliver the gene-editing enzyme complex to target cells is favored over other forms of gene delivery as it offers one-time hit-and-run gene editing, thus improving precision...